U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H27FN10
Molecular Weight 498.558
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AVAPRITINIB

SMILES

CN1C=C(C=N1)C2=CN3N=CN=C(N4CCN(CC4)C5=NC=C(C=N5)[C@@](C)(N)C6=CC=C(F)C=C6)C3=C2

InChI

InChIKey=DWYRIWUZIJHQKQ-SANMLTNESA-N
InChI=1S/C26H27FN10/c1-26(28,20-3-5-22(27)6-4-20)21-13-29-25(30-14-21)36-9-7-35(8-10-36)24-23-11-18(16-37(23)33-17-31-24)19-12-32-34(2)15-19/h3-6,11-17H,7-10,28H2,1-2H3/t26-/m0/s1

HIDE SMILES / InChI

Description

Blu-285 is a potent and selective inhibitor for hematologic malignancies with KIT Exon 17 Mutations. BLU-285 has demonstrated biochemical in vitro activity on the KIT exon-17 mutant enzyme, KIT D816V. Cellular activity of BLU-285 on KIT D816 mutants was measured by autophosphorylation in the human mast cell leukemia cell line HMC1.2, and the P815 mouse mastocytoma cell line with IC50= 4 and 22 nM, respectively. In vivo BLU-285 was well tolerated and has demonstrated dose-dependent antitumor efficacy. Complete tumor growth inhibition and ≥ 75% KIT kinase inhibition was observed with 10 mg/kg once daily, oral dosing of BLU-285 in the aggressive KIT exon 17 mutant driven P815 mastocytoma model grown as a solid tumor allograft as well as in a disseminated model of the disease. BLU-285 was also well tolerated in this in vivo model and had no adverse effects on body weight at either dose.

Approval Year

PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

In Vivo Use Guide
BLU-285 capsules or tablets for oral administration. BLU-285 will be dosed daily for 28 day cycles.
Route of Administration: Oral
In Vitro Use Guide
Cellular activity of BLU-285 on KIT D816 mutants was measured by autophosphorylation in the human mast cell leukemia cell line HMC1.2, and the P815 mouse mastocytoma cell line with IC50= 4 and 22 nM, respectively.
Name Type Language
AVAPRITINIB
USAN   INN  
Official Name English
X-720776
Code English
70C366
Code English
C-366
Code English
(S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO(2,1-F)(1,2,4)TRIAZIN-4-YL)PIPERAZIN-YL)PYRIMIDIN-5-YL)ETHAN-1-AMINE
Systematic Name English
5-PYRIMIDINEMETHANAMINE, .ALPHA.-(4-FLUOROPHENYL)-.ALPHA.-METHYL-2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO(2,1-F)(1,2,4)TRIAZIN-4-YL)-1-PIPERAZINYL)-, (.ALPHA.S)-
Systematic Name English
BLU-285
Code English
X720776
Code English
AVAPRITINIB [INN]
Common Name English
AVAPRITINIB [USAN]
Common Name English
AVAPRITINIB [WHO-DD]
Common Name English
(1S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO(2,1- F)(1,2,4)TRIAZIN-4-YL)PIPERAZIN-1-YL)PYRIMIDIN-5-YL)ETHAN-1-AMINE
Systematic Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/18/2074
Created by admin on Mon Oct 21 20:48:23 UTC 2019 , Edited by admin on Mon Oct 21 20:48:23 UTC 2019
FDA ORPHAN DRUG 506515
Created by admin on Mon Oct 21 20:48:23 UTC 2019 , Edited by admin on Mon Oct 21 20:48:23 UTC 2019
FDA ORPHAN DRUG 500415
Created by admin on Mon Oct 21 20:48:23 UTC 2019 , Edited by admin on Mon Oct 21 20:48:23 UTC 2019
Code System Code Type Description
CAS
1703793-34-3
Created by admin on Mon Oct 21 20:48:23 UTC 2019 , Edited by admin on Mon Oct 21 20:48:23 UTC 2019
PRIMARY
PUBCHEM
118023034
Created by admin on Mon Oct 21 20:48:23 UTC 2019 , Edited by admin on Mon Oct 21 20:48:23 UTC 2019
PRIMARY
INN
10613
Created by admin on Mon Oct 21 20:48:23 UTC 2019 , Edited by admin on Mon Oct 21 20:48:23 UTC 2019
PRIMARY